Diagnostic procedures for submucosal tumors in the gastrointestinal tract

Laura Graves Ponsaing, Katalin Kiss, Annika Loft, Lise Ingemann Jensen, Mark Berner Hansen

INTRODUCTION

A submucosal tumor (SMT) is defined as any intramural growth underneath the mucosa, where etiology cannot readily be determined by luminal diagnostic endoscopy or barium radiography[1].

The incidence of SMTs in the entire gastrointestinal (GI) tract is not known. However, gastric SMTs occur with an incidence of about 0.4% in diagnostic endoscopy[2]. Following the introduction of new diagnostic procedures, e.g. capsule endoscopy, a more accurate incidence may be found within the next years. Final diagnosis is made with immunohistochemistry and electron microscopy as described in part two of this series of reviews.

SMTs are usually asymptomatic and therefore most often discovered as accidental findings during surgery, autopsy or diagnostic procedures. If symptoms do occur, they are unspecific such as abdominal pain, obstruction, hemorrhage and intussusception[1,3-5]. Like other malignancies, malignant SMTs may present with systemic symptoms, especially weight loss[1,6].

The aim of this paper is to update the reader on diagnostic procedures, when investigating a lesion suspected to be a SMT in the GI tract.

DIAGNOSTIC PROCEDURES IN SUBMUCOSAL TUMORS

Standard endoscopy

Due to their lack of overt symptoms, SMTs are generally discovered accidentally during standard endoscopic examination. A lumen diminishing process with or without ulcerations is typically seen, but extramural pathology must be considered as a differential diagnosis[2]. Since standard endoscopy is not sufficient for diagnosing SMTs, suspicion of such requires further examination by means of diagnostic procedures mentioned below[7].

Capsule endoscopy

With capsule endoscopy parts of the small intestine...
inaccessible to standard endoscopy can be viewed. Its main indication is obscure hemorrhage with negative upper and lower standard endoscopic findings. A period of 8-12 h of fasting prior to the examination is required\(^9\). The capsule provides approximately 8 h of continuous endoscopic video imaging of the esophagus, stomach, small intestine and right colon. The capsule is wireless, equipped with white light-emitting diodes and has a size of approximately 1 cm × 2.5 cm. It is disposable, propelled by peristalsis and excreted after 24-48 h. There is no need for air inflation of the gut lumen. Data are transmitted employing radiotelemetry to aerials attached to the body. A study typically takes 30-60 min to review. The procedure is safe, painless, does not require sedation, can be performed ambulatory and does not have the risk of perforation as does standard endoscopy\(^8,9\).

With capsule endoscopy, a villus-based view is generated as opposed to the lumen-based view in standard endoscopy. Therefore, tumors may have a different appearance in these two procedures\(^9\). The capsule cannot wash an area, and it is not possible to re-examine a possible abnormality, take biopsies or deliver therapy as it is with standard endoscopy\(^8\) and PPE\(^10\). Furthermore, a recent study found a tendency towards poor interobserver agreement for abnormalities in relief (tumors and ulcers), but good for red-colored abnormalities (bleeding and angiodysplasia). However interobserver agreement was significantly better among experienced endoscopists than among less experienced\(^8\).

Occasionally, the capsule is caught in a stricture or diverticulum. A plain abdominal X-ray can be performed to determine whether the capsule is retained or not. However, this often happens at the site of pathology, where surgery is required anyway. Removal of an impacted capsule may be performed endoscopically\(^8\).

**Push-and-pull endoscopy**

PPE is an alternative to capsule endoscopy. With PPE the small intestine can be examined using a double-balloon technique with an oral and/or anal approach. Indications include GI bleeding, abdominal pain and surveillance of known disease. The advantage of PPE is that it is relatively safe, has a high diagnostic yield and both biopsy and endoscopic therapy can be performed\(^10\).

Disadvantages include the risk of perforation, the need for conscious sedation and the related complications, and the fact that the latex balloons used create a potential risk of anaphylactic shock in patients with latex allergy\(^10,11\).

Side effects are usually mild, such as abdominal pain for 1-2 d, brief fever, reddening of the mucosa, slight intramucosal hemorrhage in the small-bowel tissue and vomiting after the procedures. Aspiration pneumonia after an epileptic attack induced by the propofol anesthesia was found as the only complication in a recent prospective study of 100 patients\(^10\).

**Endoscopic ultrasonography**

The tool of first choice for examining SMTs in the upper GI tract is endoscopic ultrasonography (EUS). It is the most accurate procedure for detecting and diagnosing SMTs, due to its high sensitivity and specificity\(^12,16\). EUS is performed as the second intervention following standard endoscopy\(^16\).

The most important application of EUS is staging of GI malignancies, since this dictates the management and predicts survival of patients\(^15,17,18\). EUS features suggestive of malignancy are irregular borders, abnormal lymph nodes, ulcer, and a shape that is not oval or round\(^19\). Heterogeneous echopattern is a feature of controversies\(^20\).

EUS is useful in differentiating between intramural tumors, intramural vascular lesions and extraluminal impressions with or without the use of Doppler-EUS\(^3,14,23\). EUS can provide information concerning origin, size, borders, homogeneity and foci with echogenic or anechoic features (Table 1)\(^21,22,24\). In addition, EUS can indicate whether endoscopic resection is appropriate\(^13,14,20\).

In tumors smaller than 0.5 cm, high-frequency transducers can obtain information that is not available even with highly sophisticated CT, magnetic resonance imaging (MRI), transabdominal ultrasound\(^26\) or positron emission tomography (PET)\(^27\). Intramural abnormalities can be investigated with frequencies of 12 MHz, whereas 7.5 MHz reveals the extramural structures\(^21\). Its high resolution and the close proximity of the ultrasound probe to the site of the SMT makes EUS valuable in determining the layer of origin of a SMT and the possible invasion of other layers\(^21\).

However, benign SMTs, malignancies and nonneoplastic lesions, such as inflammation, can not be distinguished ensonographically\(^21,22\). Nevertheless, as EUS is a valuable tool in assessing local lymph node involvement\(^28\), this finding supports the differentiation. A study concerning EUS evaluation of leiomyomas concludes that EUS is quite observer-dependent because the interobserver agreement had a kappa value of only 0.53\(^29\). Optimally, the same examiner should perform all of the EUS examinations concerning the same patient in order to determine tumor progression versus regression.

Some important tasks of EUS in SMTs are shown in Table 1. EUS criteria for malignancy are outlined in Table 2, to which rapid growth rate found on follow-up can be added\(^30\). It must however be emphasized that only microscopic examination can determine the final diagnosis and whether the SMT is benign or malignant\(^30\).

Endosonographically, the wall of the GI tract consists of 5 layers of alternating echogenicity (Figure 1). The 1st layer is hyperechoic and represents the superficial layer of the mucosa. The 2nd layer is hyperechoic and constitutes of the deep layer of the mucosa, including the muscularis mucosae. The 3rd hyperechoic layer is the submucosa, the 4th hyperechoic the muscularis propria and the 5th hyperechoic is the serosa/adventitia\(^21,28\). As an example, a myogenic SMT can be diagnosed with confidence, if there is continuity between a hypoechoic SMT and the 4th hypoechoic, layer of the adjacent normal GI tract wall\(^30\).

**Catheter probe-endoscopic ultrasonography**

Catheter probe-endoscopic ultrasonography (CP-EUS) can probably be used instead of EUS for the evaluation of small SMTs\(^31\). The concept of CP-EUS is that an ultrasound catheter probe can be inserted through the accessory channel of a conventional endoscope. Thereby
Table 1 Macroscopic and endoscopic ultrasound features of the submucosal tumors

| Tumor Type | Endoscopic | Size | Distinct Borders | Ulcer | Layer | Form | Echogenecity | Number | Consistency |
|------------|------------|------|------------------|-------|-------|------|-------------|--------|-------------|
| GIST       | Umbilicated | < 5 cm | Yes              | Central or normal mucosa | 4\(^{\text{th}}\) (2\(^{\text{nd}}\)) | Smooth | Homo | Hypo | - | Firm |
| Granular cell tumor | Yellow | < 2 cm | Mostly no | No | 2\(^{\text{nd}}\), 3\(^{\text{rd}}\), 4\(^{\text{th}}\) | sessile polyps, nodules or plaques | Mosaic | Hypo | S (M) | Very firm |
| Ecotopic pancreas | Duct opening | 1-4 cm | Yes (no) | No | 3\(^{\text{rd}}\), 4\(^{\text{th}}\) (2\(^{\text{nd}}\), 5\(^{\text{th}}\)) | sessile, hemispherical | Perhaps hetero | Hyper | S | Firm |
| Schwannoma | Spherical (multi-nodular) | 3 cm (0.5-10 cm) | Yes (sometimes fibrous capsule) | No | 4\(^{\text{th}}\) (3\(^{\text{rd}}\)) | Round/oval (multinodular) | (Homo) | Hyper | bull’s eye | S (M) |
| Lipoma | Yellow | - | Yes, pseudocapsule | Most often intact mucosa; but ulcers do occur | 3\(^{\text{rd}}\) (4\(^{\text{th}}\), 5\(^{\text{th}}\)) | Polypoid, discrete, round | Homo | Hyper | S | Soft, compressible |
| Neurofibroma | Some times long segments of nodular thickening | Lymphangiomas: yellow | Depending on type | Yes | No | May involve all layers | Fusiform, diffuse, ‘ropelike’ or ‘bag of worms’ | Hetero | - | M | Rubbery or firm |
| Vascular | | | | | | | | | | |
| Leiomysarcoma | Exophytic | > 3 cm | Irregular | Deep ulcer (> 5 mm) | 2\(^{\text{nd}}\), 4\(^{\text{th}}\) | Nodular, polyposus | Maculopapular/nodular | Hetero | An-areas \(^2\) | S | Softer than leiomyomas |
| Kaposis’s sarcoma | Red-purple | Varying (see text) | - | Often ulceration and bleeding | 1\(^{\text{st}}\), 2\(^{\text{nd}}\), 3\(^{\text{rd}}\) | Volcanolomas, nodules, polyps, linitis plastica | Depends on the primary tumor | - | M/S | - |
| Metastases | Endo-/exophytic | - | No | Yes/No | All layers | Elliptical, multinodular/pedunculated/smooth/nodular | Homo/ hetero \(^4\) | Hypo | bull’s eye | S \(^5\) | Friable |
| GIST | Varying | > 2 cm | Yes/no | Occasionally | 4\(^{\text{th}}\) (2\(^{\text{nd}}\), 3\(^{\text{rd}}\), 5\(^{\text{th}}\)) | Elliptical, multinodular/pedunculated/smooth/nodular | Homo/ hetero | Hypo | bull’s eye | S \(^5\) | Friable |

\(1\) Hyperechoic in lymphangiomatosis \(1^{[11]}\). The anechoic areas are histologically consistent with necrotic areas \(1^{[21]}\). \(2\) Neurofibromatosis type 1 is associated with gastrointestinal stromal tumors (GIST). GIST are often multiple in neurofibromatosis type 1 \(1^{[16]}\). Normally gastrointestinal stromal tumors are homogenic, but if the tumor is large, central necrosis (cystic spaces) can result in heterogeneity \(2^{[30]}\). Furthermore, echogenic foci and calcifications may be seen \(2^{[34]}\). A hyperechoic, marginal halo resulting in a bull’s eye appearance of the SMT \(1^{[16]}\). Homo: homogenic; Hetero: heterogeneous; Hypo: hypoechoic; Hyper: hyperechoic; An: anechoic. - means no data was found on the subject.

Both endoscopy and EUS can be performed during the same intervention \(1^{[16,31]}\). The clinician should bear in mind that CP-EUS images tend to be more hypoechoic than EUS images \(1^{[19]}\).

Due to the small diameter of the CP-EUS probe and the absence of a balloon at its tip, compression of the inner layers is avoided and thus blurring \(1^{[16]}\). CP-EUS identifies the layer of origin of myogenic SMTs with great precision and is better than EUS at distinguishing between the two layers of the muscularis propria \(1^{[16]}\).

In a recent study, CP-EUS diagnosed more than 95% correctly in large intestinal SMTs, confirmed by biopsy or surgical resection \(1^{[18]}\). Another study of 25 SMTs, showed that CP-EUS and EUS equally visualized all SMTs, with image quality and determination of tumor diameters and margins being comparable \(1^{[14]}\). On the contrary, Chak et al \(1^{[11]}\) found that CP-EUS, but not EUS, staged submucosal lesions correctly in all cases, confirmed by histology. Staging of regional cancer was concordant between EUS and CP-EUS in 80% of the cases. However, these results may be influenced by a selection bias, as only smaller SMTs were chosen for CP-EUS examination.

A shortcoming of CP-EUS is the risk of neglecting other SMTs, since examination occurs only directly at the region of interest \(1^{[10]}\). Due to its smaller diameter it could be suspected that CP-EUS would have an advantage in stenosing SMTs that cannot be traversed by an EUS-endoscope. However, stenosing tumors tend to be bulky,
and since CP-EUS has limited depth penetration compared to EUS, CP-EUS may fail to visualize the extraluminal margin and assess adjacent lymph nodes\(^{[31]}\). If the SMT is larger than 5 cm in diameter, EUS or CT may be the preferable imaging techniques\(^{[16]}\).

**Condom-catheter probe-endoscopic ultrasonography**

In the esophagus, the acoustic coupling needed for EUS is impaired by the lack of a water-filled lumen. Therefore a method has been developed specifically for this situation: small-diameter CP-EUS with an attached latex condom (condom-CP-EUS) that can be filled with water\(^{[33]}\).

A limitation of condom-CP-EUS, when using large echoendoscopes, is compression of small esophageal tumors and thus distortion of the image\(^{[33]}\). The wall layers are also often compressed, and therefore only 3 layers of the esophageal wall are seen, compared to the 5 layer pattern with 7.5-12 MHz probes\(^{[21]}\).

Other shortcomings are limited depth penetration and poor acoustic coupling, resulting in low quality images and impeded evaluation of lymph nodes and bulky SMTs. Moreover, a large volume of water is needed for adequate acoustic coupling, which may leak and cause aspiration. Large SMTs may create air artifacts between the condom and the esophageal wall\(^{[33]}\). Additionally, there is a potential risk of anaphylactic shock, due to latex allergy, which has a prevalence of less than 1% in the normal population\(^{[11]}\).

**Three dimensional endoscopic ultrasonography**

The need for three-dimensional (3D) EUS has arisen as a consequence of the difficulty less experienced endosonographers witness interpreting two-dimensional (2D) EUS images\(^{[34]}\). Indeed, 3D-EUS, compared to 2D-EUS, is relatively easy to use and the examination time will not be extended, as it is possible to view the whole lesion and perform a new scan immediately after a poor scan result\(^{[36]}\).

However, some criterions are to be fulfilled in order to create a good image. The probe must be parallel and close to the mucosal surface. This is difficult in the stomach, but relatively easy in the esophagus, though probe wobbling can be caused by the peristalsis, respiratory movement

---

**Table 2  Endoscopic ultrasonographic criteria for malignancy in different SMTs**

| Reference       | Tumor type | Criteria for determining the SMT as malignant or borderline | Size | Irregular borders | Abnormal regional lymph nodes | Heterogeneous echo pattern | Cystic spaces | Echo-genic foci | Shape not oval/round | Ulcer |
|-----------------|------------|-----------------------------------------------------------|------|-------------------|-------------------------------|---------------------------|---------------|-----------------|---------------------|-------|
| Ando et al 2002\(^{[30]}\) | GIST       | Size > 5 cm and at least 1 of the 2 other features: | > 5 cm | Yes              | -                             | Yes                       | -             | -               | -                   | -     |
| Nickl et al 2002\(^{[20]}\) | Hypo-echoic SMTs | 1 or more of the features: | > 3 cm | Yes              | Yes                           | No                        | No            | Yes            | Yes                 | -     |
| Brand et al 2002\(^{[24]}\) | SMTs in general | 2 or more of the features or 1 and clinical symptoms (pain, dysphagia, weight loss, hemorrhage) | > 3 cm | Yes              | -                             | Heterogeneous echo pattern | -             | -               | -                   | -     |
| Rösch et al 2002\(^{[12]}\) | SMTs in general | 2 or more of the features: | > 3 cm | Yes              | Yes                           | Heterogeneous echo pattern | -             | -               | -                   | -     |
| Palazzo et al 2000\(^{[23]}\) | GIST       | 2 or more of the features: | -     | Yes              | Yes                           | Yes                       | -             | -               | -                   | -     |
| Chak et al 1997\(^{[11]}\) | GIST       | 2 or more of the features: | > 4 cm | Yes              | > 4 mm                        | > 3 mm                    | -             | -               | -                   | -     |

Nickl and coworkers\(^{[20]}\) had the highest sensitivity rate (100%) while Palazzo and coworkers\(^{[23]}\) had the highest specificity rate (88%). -: means that this feature was not part of the criteria in the given study.
or cardiac impulse. Furthermore, the time factor is critical, as the risk of probe wobbling increases with the time needed for completing a scan. In an investigation it took 3-4 s to complete a scan as opposed to 3-5 min in another investigation. More recent publications show promising results concerning the reduction of the time needed for processing the scans. Finally, the size of the SMT is crucial. Due to the limited depth penetration in these probes, the results of 3D-EUS are better when applied to small SMTs, although the size of small SMTs (<1 cm) tends to be overestimated by 3D-EUS.

3D-EUS data on GI SMTs are however sparse. Thus, data on mucosal cancer is used in this paper to give an impression of 3D-EUS in practice. In a study of 43 upper GI lesions, depth staging was correct in 80% of the cases of esophageal cancer and almost 70% of the cases of gastric cancer, histologically confirmed. However, only 37% of the 3D-EUS images were of an acceptable quality, which meant that several images had to be made for each lesion.

**Endoscopic ultrasound guided fine needle aspiration**

Since it is impossible to differentiate definitely between benign and malignant SMTs by means of any imaging technique, histological or cytological confirmation is a necessity. A study shows that only in 35% of cases was an acceptable submucosal representation achieved with forceps biopsy during standard endoscopy, even though the endoscopist intended to obtain submucosal tissue. On the contrary, endosonographically performed fine needle aspiration (EUS-FNA) is a good method for obtaining cytological samples.

In EUS-FNA the aspiration needle can be inserted more precisely into the SMT than in percutaneous FNA. Moreover, the incidence of malignant seeding is relatively low. This may, however, be the result of selection bias: more biopsies are performed percutaneously and therefore more cases of cutaneous seeding than mucosal are seen. These advantages may be outweighed, though, by the risks of conscious sedation in endoscopy.

EUS-FNA contributes to solving therapeutic dilemmas. A study showed that due to the result of EUS-FNA the decision to abandon surgery was directly affected in 26% of patients with primary malignancies. The reason for this was severe malignancy, such as distant nodal metastasis. The sensitivity of cytological samples achieved through EUS-FNA has been reported to be 88%-91% and the specificity close to a 100% for the diagnosis of malignant lesions confirmed by the surgical findings or long-term clinical follow-up. However, as some investigators point out, in order to obtain an adequate cytological sample, the optimal situation is that a cytologist is present during the procedure. Furthermore, there are different ways of handling the cytological samples obtained by EUS-FNA, such as performing smears and cell-blocks. It must be emphasized that neither mitotic counts nor immunohistochemistry can be performed on smears. Therefore the optimal situation is when cell blocks are made from the cytological sample. If the number of cells is too small to count mitotic figures per 50 high power fields, immunohistochemical staining with MIB-1 (a proliferation marker) can provide information of the cellular activity.

Sometimes examination of the whole SMT is needed in order to differentiate between benign and malignant, and a pitfall is the aspiration of normal smooth-muscle cells. If possible, cells should be obtained from different parts of the SMT using a large needle (18-20G).

Complications to EUS-FNA appear to be rare, as two investigations have shown a complication rate of 0%-2%. However, careful Doppler-EUS examination must always be performed prior to EUS-FNA in order to prevent rupture of a possible varix.

**Barium-contrast in X-ray**

Barium studies can reveal several pathological conditions, such as submucosal infiltration, ulceration, mass presence and lumen stenosis, which may all be present in SMTs. Barium studies are also valuable in assessing the extent and multiplicity of SMTs. The typical appearance of a SMT is an intramural mass with intact or ulcerated overlying mucosa. The tumor is seen as a smoothly circumscribed mass, when seen en face and the margins as obuse or right angles, when viewed in profile. However, barium studies are limited to exophytic masses, and in staging and detection of early or subtle SMTs this method is of little value.

**Computed tomography**

Recent advances in CT have drawn attention to the use of CT for evaluating the GI tract. Cross-sectional CT has the primary role in staging GI tumors. New multi-slice CT has some advantages compared to single-slice spiral scanners, such as elimination of motion artifacts and acquisition of thinner sections. This improves the quality of 3D data, but the thin collimation involves an increase in the radiation dose to the patient. CT has an advantage compared with EUS, namely the possibility of delineating the full extension of the tumor. The forces of CT are demonstration of a tumor, its size, relation to adjacent organs and revelation of metastasis, and therefore are the tasks of CT primarily staging, surgical planning and follow-up.

CT cannot classify SMTs as demonstrated in a recent study, where CT was inconclusive in more than 50% of GI stromal tumors (GISTs). CT cannot either differentiate between malignant and benign SMTs, unless obvious local invasion or metastases are present. CT, especially CT angiography, is valuable for the detection of gastric varices. In large and exophytic gastric stromal tumors, 3D-CT can be helpful in better characterizing the mass and determining its origin.

Traditional oral contrast agents of high attenuation have some disadvantages when evaluating the GI tract. An example is when the contrast does not mix uniformly with gastric contents, resulting in the creation of pseudotumors. Therefore water, which is of low attenuation, is preferred as an oral contrast agent. Simultaneously non-ionic contrast material is given intravenously, which enhances the GI walls. Furthermore, adequate distension of the stomach is important for proper imaging.
latter may result in overlooked disease or the collapsed gastric wall mimicking disease\textsuperscript{48}.

**Magnetic resonance imaging**

Like CT, MRI is valuable in diagnosis and evaluating the extent of the tumor, including staging\textsuperscript{49,50}. However, due to variable and non-specific appearances, MRI offers no additional information compared to CT concerning the internal features of, at least, GISTs\textsuperscript{49}.

Concerning limitations in both CT and MRI, it can be difficult to determine the organ of origin from cross sectional imaging alone in the presence of a significantly exophytic tumor\textsuperscript{51}. However, MRI is a helpful adjunct to CT, especially concerning large SMTs, where the multiplanar capability of magnetic resonance can aid the determination of organ of origin, the relationship to other organs and delineate the major blood vessels. The new multi-channel CT-scanners have the same capability and may become the method of choice. In GISTs, the solid parts of the tumor are typically of low signal-intensity on T1-weighted images, but high signal-intensity on T2-weighted images. However, the degree of necrosis and hemorrhage greatly affect the signal-intensity pattern. Depending on the age of the hemorrhage, the signal-intensity will vary from high to low on both T1- and T2-weighted images. Due to gadolinium enhancement in viable tumor tissue, areas of necrosis can be outlined\textsuperscript{52}.

**Positron emission tomography**

In the recent years PET has shown to have great value primarily in the early assessment of response in GISTs to treatment with imatinib\textsuperscript{48,52-54}. The reason for its effectiveness lies in the radionabeled surrogate marker for glucose metabolism, fluorodeoxyglucose (FDG). FDG highlights areas of the body with enhanced metabolism, such as malignant SMTs\textsuperscript{48}. Metabolic changes occur prior to morphological changes, which explains why several investigations conclude that PET is superior to CT and MRI in predicting early response to therapy\textsuperscript{44,46,53}. A recent investigation on GISTs concludes that FDG-PET can separate imatinib-responders from -non-responders as early as 1 wk after initiation of treatment\textsuperscript{54}. Furthermore, PET is indicated in cases, where equivocal CT- or MRI-images suspect metastases\textsuperscript{55}. The risk of misinterpretation is minimized with the new combined PET/CT scanners uniting functional and morphologic imaging\textsuperscript{27}.

With PET, not only is the evaluation of response to therapy facilitated, but also the determination of the diagnosis, recurrence, staging and extent of disease\textsuperscript{48,54,55}.

To the disadvantages of PET count the fact that the acquisition time is 3-5 min per bed position. Due to respiratory motion, very small SMTs (< 5 mm) may be blurred and therefore missed\textsuperscript{56}.

As FDG is not a specific cancer tracer, uptake is seen in cicatrices following surgery due to benign inflammation, and therefore PET scans should not be performed until 3-4 wk after surgery to avoid these artifacts mimicking tumors. Other situations with increased uptake are tense muscles, catheters, tubes, stomas, the bone marrow in patients treated with chemotherapy and excretion of FDG to the urinary tract\textsuperscript{57}. Physiological excretion of FDG can also be seen in the bowel, which can be difficult to differentiate from SMTs. Furthermore, it must be taken into consideration that slowly growing tumors, such as benign SMTs, only rarely absorb FDG. Moreover, hyperglycemia and administration of insulin may alter the distribution of FDG. Therefore at least 5 h of fasting and measurement of the blood glucose level prior to the scan is recommended\textsuperscript{57}.

**Benign Tumors**

For all of the SMTs mentioned below, the endoscopic, EUS and macroscopic features can be seen in Table 1, and an EUS image of a leiomyoma and a lipoma is shown in the Figure 1.

**Leiomyomas**

Leiomyomas are the commonest mesenchymal tumors in the esophagus\textsuperscript{58} as opposed to the rest of the GI tract, where GISTs are the most frequent\textsuperscript{44}. Leiomyomas are found in the esophagus, colon and rectum, but are very rare in the stomach and small intestine\textsuperscript{58}.

Differential diagnoses to leiomyomas are preoperatively mostly leiomyosarcomas and, in the esophagus, carcinomas\textsuperscript{59}.

**Schwannomas**

GI Schwannomas are rare. Their ratio to GISTs, the most frequent GI SMTs, is approximately 1:50-100\textsuperscript{58}. They are mostly found in the stomach.

**Granular cell tumor**

In the GI tract granular cell tumor mostly involves the middle to distal parts of the esophagus, with 1/3 of all the GI cases occurring at this site\textsuperscript{60}. They are solitary in 80%-90% of all cases\textsuperscript{61,62}.

**Heterotopic pancreatic tissue**

Heterotopic pancreatic tissue is mostly located within 3-4 cm on both sides of the pylorus, but may occur in Meckel’s diverticulum and rarely in the small intestine. Heterotopic pancreas is a nonneoplastic\textsuperscript{22}, congenital tumor thought to be a result of separation of fragments from the main pancreatic mass due to the rotation of the foregut\textsuperscript{58,64,65}. An investigation found heterotopic pancreas in 0.25% of all explorative laparotomies\textsuperscript{66}.

A distinctive feature of heterotopic pancreatic tissue may be the presence of an opening, visible as a dimple on the surface\textsuperscript{64}, from which fluid may trickle on pressure\textsuperscript{64}. Concerning differential diagnoses, both carcinoid tumors and heterotropic pancreatic tissue appear hypoechoic and irregular endosonographically\textsuperscript{21}.

**Lipomas**

GI lipomas occur throughout the GI tract, but are undoubtedly most frequent in the colon as a solitary, slowly growing, benign tumor, originating within the submucosa and protruding into the lumen\textsuperscript{43,59}.

CT findings are a well-circumscribed, submucosal lesion with uniform fat attenuation and, occasionally, a fibrous capsule\textsuperscript{5}. X-ray criteria for lipomas are changing size and shape during the course of examination, reflecting their soft consistency\textsuperscript{59}.
Differential diagnoses from the endoscopic appearance are leiomyoma, neurofibroma, adenomatous polyp and villose adenoma. Differentiation is based on consistency, polypoid features and surface pattern of the different tumors.

**Neurofibromatosis type 1**

Solitary neurofibromas are rare. Therefore, neurofibromatosis should be suspected when neurofibromas are encountered. Neurofibromatosis type 1 (NF1, von Recklinghausen Disease) is relatively common with a prevalence of 1/3000 births in Western countries. The neurofibroma is derived from perineural cells on peripheral nerves. GI involvement is common in NF1. These SMTs have a predilection for the duodenum, especially the ampulla of Vater.

NF1 is associated with gliomas, meningiomas, phaeochromocytomas, hemangiomas and GISTs. In the latter, the incidence of GISTs may be 200 times the incidence in an unaffected population. The GISTs in patients with NF1 tend to be multiple. Furthermore, it should be kept in mind that NF1 is also associated with carcinoid tumors that tend to occur at the ampulla of Vater, like the neurofibromas. The explanation for this co-location may be a transformation of an endo-ectodermal complex located near the ampulla of Vater in NF1-patients.

**Vascular tumors**

- **Hemangiomas**: Multiple hemangiomas may be found, as in the blue rubber-bleb nevi syndrome that mostly affects the skin and GI tract. Approaches to diagnosing vascular lesions are typically Doppler-EUS and CT-angiography, but a 99mTc-labeled redcell scan may also be performed to reveal hemangiomas or other transiently or mildly bleeding lesions. EUS is valuable in evaluating the mode of spread, site of origin and the pathology.

- **Lymphangiomas**: Lymphangiomas are rare, probably hamartomatous, anomalies that occur solitarily, mostly in the duodenum. Endoscopically, yellow-tan lesions are seen, occasionally with satellite lesions. When biopsy is performed, exudation of yellow chylous liquid is seen.

**MALIGNANT TUMORS**

**Leiomyosarcomas**

Leiomyosarcomas are mostly found in the small intestine, where they constitute more than 10% of all malignant lesions, and mostly behave in a highly malignant fashion. A palpable abdominal mass may be encountered in almost 50% of cases of leiomyosarcomas in the small intestine.

Endoscopically, leiomyosarcomas are as a rule single and have a predominantly exophytic component. Radiologically, excavated leiomyosarcomas may be confused with lymphomas and metastatic melanomas. Leiomyosarcomas are expected to have a higher glucose metabolism than leiomyomas, and thus PET or PET/CT could aid the differentiation. In addition, the EUS criteria mentioned in Table 1 may be helpful.

**Gastrointestinal Kaposi’s sarcoma**

The causative viral agent of Kaposi’s sarcoma is human herpes virus 8. Kaposi’s sarcoma is considerably more frequent in men than women and is mostly caused by immunosuppression, especially HIV.

Endoscopically, Kaposi’s sarcomas may be mucosal, but are usually submucosal and either isolated or extensively involve the bowel wall. All parts of the GI tract are at risk.

In the esophagus, acquired immunodeficiency syndrome-related lymphoma should be considered as a differential diagnosis, when viewed radiologically.

**Metastases in the gastrointestinal tract**

The most frequent primary tumors that result in GI metastases are breast cancer, melanoma and lung cancer. The occurrence of metastases to the stomach from fatal breast cancer has been reported to be 8%. Metastases may be brought about by hematogenic or lymphatic spread or seeding through the peritoneum.

Endoscopic findings are mainly sorted under three morphological features: nonulcerative SMTs, SMTs with elevation and ulceration at the apex (volcano lesions), and multiple nodules of varying sizes with tip ulceration. EUS is valuable in evaluating the mode of spread, site of origin and the pathology.

**Gastrointestinal stromal tumors**

GISTs are the commonest mesenchymal tumors in the GI tract. The annual incidence is estimated to be at least 10 to 20 cases per million. Their origin is supposedly multipotential mesenchymal stem cells, and therefore both myogenic and neurogenic features may be present. GI autonomic nerve tumors (GANTs), are now categorized under GIST owing to their great immunohistochemical and ultrastructural resemblance.

65% of GISTs occur in the stomach, 30%-35% in the small intestine and 5%-10% in the colon. Colonic GISTs have a high proportion of malignancy. Endosonographically, large size, lobulation, irregular borders and echogenic foci indicate malignancy. CT, the signs that indicate a highly malignant tumor are calcification, ulceration, necrosis, cystic areas, fistula, metastasis, ascites and infiltration.

Endoscopic differential diagnoses are gastric lymphoma and an inflammatory fibroid polyp. Endoscopically, excavated leiomyosarcomas may be confused with lymphomas and metastatic melanomas. Leiomyosarcomas are expected to have a higher glucose metabolism than leiomyomas, and thus PET or PET/CT could aid the differentiation. In addition, the EUS criteria mentioned in Table 1 may be helpful.

**CONCLUSION**

Standard endoscopy, capsule endoscopy, push-and-pull enteroscopy, barium contrast X-ray and forceps biopsies can not differentiate between extraluminal compression and SMTs. Therefore, there is a need for EUS or whole
body imaging procedures as well as in the diagnosis of SMTs. EUS with biopsy is the first choice of diagnostic tool, but if depth penetration is improved in CP-EUS, this may be preferred due to the reduced number of intubations and examination time. So far 3D-EUS has not shown acceptable results, but it is expected to facilitate the assessment of borders, extent and size of SMTs in the future. Still, EUS is rather subjective and therefore the reproducibility of the results is reduced.

Biopsies should only be obtained, if the outcome could lead to a cancellation of a planned operation, due to the risk of malignant seeding in any malignant SMTs and due to the risk of hemorrhage if biopsies are taken from GISTs because of their brittleness.

Even in GISTS responsive to imatinib therapy, tumor size may decrease over months or not at all. Therefore, with CT it may take months to reach conclusions regarding GIST responsiveness, whereas FDG-PET determines this within days to weeks after commenced treatment. However, unless short-term follow-up is needed, CT is a sufficient way of monitoring. The quality of multi-slice CT is now comparable to MRI, but MRI has the advantage of disclosing necrosis, due to the enhancement of gadolinium in viable tumor tissue. MRI is especially an option when assessing liver metastases, while FDG-PET detects even small, malignant SMTs that may be overlooked by other diagnostic methods. Thus PET or PET/CT are recommendable for SMTs larger than 5 mm whereas (CP-) EUS is preferred for SMTs smaller than 5 mm.

ACKNOWLEDGMENTS

We thank PH Zhou for his endosonographic image.

REFERENCES

1. Chak A. EUS in submucosal tumors. Gastrointest Endosc 2002; 56: 543-548
2. Hedenbro JL, Ekelund M, Wetterberg P. Endoscopic diagnosis of submucosal gastric lesions. The results after routine endoscopy. Surg Endosc 1991; 5: 20-23
3. Gill SS, Heuman DM, Mihas AA. Small intestinal neoplasms. J Clin Gastroenterol 2001; 33: 267-282
4. Day D, Jass J, Price A et al Morson & Dawson's Gastrointestinal Pathology. Massachusetts: Blackwell Science Ltd, 2003
5. Moues CM, Steenvoorde P, Viens EA, von Groningen K, de Bruijn JF. Jejunal intussusception of a gastric lipoma: a review of literature. Dig Surg 2002; 19: 418-420
6. Hsu CC, Chen JJ, Changchien CS. Endoscopic features of metastatic tumors in the upper gastrointestinal tract. Endoscopy 1996; 28: 249-253
7. Knoop M, St Friedrichs K, Dierschke J. Surgical management of gastrointestinal stromal tumors of the stomach. Langenbecks Arch Surg 2000; 385: 194-198
8. Swain P, Adler D, Enns R. Capsule endoscopy in obscure intestinal bleeding. Endoscopy 2005; 37: 655-659
9. De Leusse A, Landi B, Edery J, Burtin P, Lecomte T, Seksik P, Bloch F, Jian R, Cellier C. Video capsule endoscopy for investigation of obscure gastrointestinal bleeding: feasibility, results, and interobserver agreement. Endoscopy 2005; 37: 617-621
10. Eh C, May A, Nachbar L, Cellier C, Landi B, di Caro S, Gasbarrini A. Push-and-pull enteroscopy in the small bowel using the double-balloon technique: results of a prospective European multicenter study. Endoscopy 2005; 37: 613-616
11. Turjamanmaa K, Mäkinen-Kiljunen S. Latex allergy: prevalence, risk factors, and cross-reactivity. Methods 2002; 27: 10-14
12. Rösch T, Kapfer B, Will U, Baronius W, Strobel M, Lorenz R, Ulm K. Accuracy of endoscopic ultrasonography in upper gastrointestinal submucosal lesions: a prospective multicenter study. Scand J Gastroenterol 2002; 37: 536-62
13. Shim CS, Jung IS. Endoscopic removal of submucosal tumors: preprocedure diagnosis, technical options, and results. Endoscopy 2005; 37: 646-654
14. Hizawa K, Matsumoto T, Kouzuki T, Suekane H, Esaki M, Fujishima M. Cystic submucosal tumors in the gastrointestinal tract: endosonographic findings and endoscopic removal. Endoscopy 2000; 32: 712-714
15. Hünrein M, Dohmoto M, Haensch W, Schlag PM. Endosonography-guided biopsy of mediastinal and pancreatic tumors. Endoscopy 1998; 30: 32-36
16.Buscarini E, Stasi MD, Rossi S, Silva M, Giangregorio F, Adriano Z,Buscarini L. Endosonographic diagnosis of submucosal upper gastrointestinal tract lesions and large fold gastropathies by catheter ultrasound probe. Gastrointest Endosc 1999; 49: 184-191
17. Nakazawa S. Recent advances in endoscopic ultrasonography. J Gastroenterol 2000; 35: 257-260
18. Nakazawa S, Inui K. Endosonography and endoscopic magnetic resonance imaging. Baillieres Best Pract Res Clin Gastroenterol 1999; 13: 21-31
19. Polkowski M. Endoscopic ultrasound and endoscopic ultrasound-guided fine-needle biopsy for the diagnosis of malignant submucosal tumors. Endoscopy 2005; 37: 635-645
20. Nickl N, Gress F, McClave S, Fockens P, Chak A, Savides T, Catalano M, Behling C, Odegaard S, Chang K, Rosch T, Hawes R, Scheiman J, Sahai A, Sivak M, Isenberg G, Hoffman B, Aabakken L, Jowell P, Jones W, Kinney M, Schmitt C. Hypoechoic intramural tumor study: final report. Gastrointest Endosc 2002; 55: A589
21. Fockens P. Current endosonographic possibilities in the upper gastrointestinal tract. Baillieres Clin Gastroenterol 1994; 8: 603-619
22. Wiech T, Walch A, Werner M. Histopathological classification of nonneoplastic and neoplastic gastrointestinal submucosal lesions. Endoscopy 2005; 37: 630-634
23. Palazzo L, Landi B, Cellier C, Cuillerier E, Roseau G, Barbier JP. Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours. Gut 2000; 46: 88-92
24. Brand B, Oesterhelweg L, Binmoeller KF, Srimav P, Bohnacker S, Seewald S, De Weerth A, Soehendra N. Impact of endoscopic ultrasound for evaluation of submucosal lesions in gastrointestinal tract. Dig Liver Dis 2002; 34: 290-297
25. Waxman I, Saito Y, Rauj GS, Watari J, Yokota K, Reeves AL, Kohgo Y. High-frequency probe EUS-assisted endoscopic mucosal resection: a therapeutic strategy for submucosal tumors of the GI tract. Gastrointest Endosc 2002; 55: 44-49
26. Liu JB, Goldberg BB. 2-D and 3-D endoluminal ultrasound: vascular and nonvascular applications. Ultrasound Med Biol 1999; 25: 159-173
27. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, Bockisch A, Debatin JF, Freudenberg LS. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45: 357-65
28. Miettinen M, Blay JY, Sobin LH, Kindblom LG. World Health Organization classification of tumors. Pathology and genetics of tumor of digestive system. Lyon: IARC Press, 2000: 103-143
29. Gress F, Schmitt C, Savides T, Faigel DO, Catalano M, Wassef W, Rouben L, Nickl N, Ciaccia D, Bhutani M, Hoffman B, Affronti J. Interobserver agreement for EUS in the evaluation and diagnosis of submucosal masses. Gastrointest Endosc 2001; 53: 71-76
30. Ando N, Goto H, Niwa Y, Hirooka Y, Ohmiya N, Nagasaka T, Hayakawa T. The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis. Gastrointest Endosc 2002; 55: 37-43
31. Chak A, Soweid A, Hoffman B, Stevens P, Hawes RH, Lightdale CJ, Cooper GS, Canto MJ, Sivak MV. Clinical
implications of endoluminal ultrasonography using through-the-scope catheter probes. Gastrointest Endosc 1998; 48: 485-490
32. Zhou PH, Yao LQ, Zhong YS, He GJ, Xu MD, Qin XY. Role of endoscopic miniprobe ultrasonography in diagnosis of submucosal tumor of large intestine. World J Gastroenterol 2004; 10: 2444-2446
33. Wallace MB, Hoffman BJ, Sahai AS, Inoue H, Van Velse A, Hawes RH. Imaging of esophageal tumors with a water-filled condom and a catheter US probe. Gastrointestinal Endosc 2000; 51: 597-600
34. Tokiyama H, Yanai H, Nakamura H, Takeo Y, Yoshida T, Okita K. Three-dimensional endoscopic ultrasonography of lesions of the upper gastrointestinal tract using a radial-linear switchable thin ultrasound probe. J Gastroenterol Hepatol 1999; 14: 1212-1218
35. Watanabe M, Kida M, Yamada Y, Sainenji K. Measuring tumor volume with three-dimensional endoscopic ultrasonography: an experimental and clinical study (including video). Endoscopy 2004; 36: 976-981
36. Sumiyama K, Suzuki N, Kakutani H, Hino S, Tajiri H, Suzuki H, Aoki T. A novel 3-dimensional EUS technique for real-time visualization of the volume data reconstruction process. Gastrointestinal Endosc 2002; 55: 723-728
37. Nishimura K, Niwa Y, Goto H, Hase S, Arisawa T, Hayakawa T. Three-dimensional endoscopic ultrasonography of gastrointestinal lesions using an ultrasound probe. Scand J Gastroenterol 1997; 32: 862-868
38. Kojima T, Takahashi H, Parra-Blanco A, Kohsen K, Fujita R. Diagnosis of submucosal tumor of the upper GI tract by endoscopic resection. Gastrointestinal Endosc 1999; 50: 516-522
39. Chang KJ, Katz KD, Durbin TE, Erickson RA, Butler JA, Lin F, Wuerker RB. Endoscopic ultrasound-guided fine-needle aspiration. Gastrointestinal Endosc 1994; 40: 694-699
40. Horton KM, Fishman EK. Current role of CT in imaging of the stomach. Radiographics 2003; 23: 75-87
41. Greiss FG, Hawes RH, Savides TJ, Ikenberry SO, Lehman GA. Endosonographic fine-needle-aspiration biopsy using linear array and radial scanning endoscopy. Gastrointestinal Endosc 1997; 45: 243-250
42. Okubo K, Yamao K, Nakamura T, Tajika M, Sawaki A, Harak K, Kawai H, Yamamura Y, Mochizuki Y, Koshikawa T, Inada K. Endoscopic ultrasound-guided fine-needle aspiration biopsy for the diagnosis of gastrointestinal stromal tumors in the stomach. J Gastroenterol 2004; 39: 747-753
43. Courtoisyllenis N, Grammatikakis J, Prassopoulos P. Role of conventional radiology in the diagnosis and staging of gastrointestinal tract neoplasms. Semin Surg Oncol 2001; 20: 91-108
44. Lau S, Tam KF, Kam CK, Lui CY, Siu CW, Lam HS, Mak KL. Imaging of gastrointestinal stromal tumour (GIST). Clin Radiol 2004; 59: 487-498
45. Levy AD, Remotti HE, Thompson WM, Sobin LH, Miettinen M. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics 2005; 23: 283-304, 456; quiz 532
46. El-Zohairy M, Khalil el-SC, Fakhri I, El-Shahawy M, Gouda I. Gastrointestinal stromal tumor (GIST)’s surgical treatment, NCI experience. J Egypt Natl Canc Inst 2005; 17: 56-66
47. Blay JY, Bonvalot S, Casali P, Chou H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hoang Duong PC, Janssen H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichard P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the ESMO Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-578
48. Stroobants S, Goeminne J, Seegers M, Dimitrjevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, Dunem H, Silberman S, Mortelmans L, van Oosterom A, 18FDG-Positron emission tomography for the early prediction of response in advanced gastrointestinal stromal tumors treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012-2020
49. Campos FG, Leite AF, Araújo SE, Atui FC, Seid V, Habr-Gama A, Kiss DR, Gama-Rodrigues J. Anorectal leiomyomas: report of two cases with different anatomical patterns and literature review. Rev Hosp Clin Fac Med Sao Paulo 2004; 59: 296-301
50. Giuly JA, Picand R, Giuly D, Menges B, Nguyen-Cat R. Von Recklinghausen disease and gastrointestinal stromal tumors. Am J Surg 2003; 185: 86-87
51. Levy AD, Remotti HE, Thompson WM, Sobin LH, Miettinen M. Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation. AJR Am J Roentgenol 2003; 180: 1607-1612
52. Blasberg RG, Tjuvajev JG. Molecular-genetic imaging: current and future perspectives. J Clin Invest 2005; 111: 1620-1629
53. Reddy MP, Reddy P, Lillien DL. F-18 FDG PET imaging in gastrointestinal stromal tumor. Clin Nucl Med 2003; 28: 677-679
54. Jalger PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nat Med Commun 2004; 25: 433-438
55. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45: 17-21
56. Wilkinson MD, Fulham MJ, FDG PET imaging of metastatic gastrointestinal stromal tumor. Clin Nucl Med 2003; 28: 780-781
57. Bhardwaj P, Zhuang H, Kumar R, Charon M, Alavi A. Lactogentic artifacts on whole-body F-18 FDG PET imaging. Clin Nucl Med 2004; 29: 429-439
58. Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12
59. Hatch GF, Wertheimer-Hatch L, Hatch KF, Davis GB, Blanchard DK, Foster RS, Skandalakis JE. Tumors of the esophagus. World J Surg 2000; 24: 401-411
60. Palazzo L, Landi B, Cellier R, Gousseau S, Bhuiyan A, Barbiere D. Endosonographic features of esophageal granular cell tumors. Endoscopy 1997; 29: 850-853
61. Norberto L, Urso E, Angirman I, Kizimoto R, Erroi F, Marini S, Tosato S, Ruffolo C, D’Amico DF. Yttrium-aluminum-garnet laser therapy of esophageal granular cell tumor. Surg Endosc 2002; 16: 361-362
62. Nakachi A, Miyazato H, Oshiro T, Shimohi H, Shiraishi M, Muto Y. Granular cell tumor of the rectum: a case report and review of the literature. J Gastroenterol 2000; 35: 631-634
63. Odze RD, Antonioli DA, Wallace MB, Thomas Jr CR, Keohan ML, Hibschoo H, Antman KH. Gastrointestinal Cancers—A comparison to Steisenger and Fordtran’s Gastrointestinal and Liver Disease. Spain: Elsevier Science Limited, 2003: 265-266, 761, 724
64. Nickels J, Laasonen EM. Pancreatic heterotopia. Scand J Gastroenterol 1970; 5: 639-640
65. Tanaka K, Tsunoda T, Eto T, Yamada M, Tajima Y, Shimogama H, Yamaguchi T, Matsu S, Izawa K. Diagnosis and management of heterotopic pancreatic tissue. Int Surg 1993; 78: 32-35
66. Sloots CE, de Brauw LM, Bot FJ, Greve JW. False-positive cytology in diagnostic laparoscopy due to ectopic pancreas. Dig Surg 1999; 16: 434-436
67. Fernandez MJ, Davis RP, Nora PF. Gastrointestinal lipomas. Arch Surg 1985; 118: 1081-1083
68. Crowe F, Schull W, Neel J. A Clinical, Pathological and Genetic Study of Multiple Neurofibromatosis. Springfield, IL, Charles C. Thomas, 1956
69. Stevens A, Lowe J, Young B. Wheeler’s Basic Histopathology—a colour atlas and text. Edinburgh, London, New York, Philadelphia, St. Louis, Sydney, Toronto, Churchill Livingstone, 2002
70. Levy AD, Patel N, Dow N, Abbott RM, Miettinen M, Sobin LH. From the archives of the AFIP: abdominal neoplasms in patients with neurofibromatosis type I: radiologic-pathologic correlation. Radiographics 2005; 25: 435-440
71. Hirsch NP, Murphy A, Radcliffe JF. Neurofibromatosis: clinical presentations and anaesthetic implications. Br J Anaesth 2001; 86: 555-564
